Ocular Disorders: Rising Therapeutics, Technologies, and Devices
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
NEW YORK, Jan. 20, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers a handful of companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while alsoproviding alternative therapeutic options for various ocular complications. In an interview with several companies including Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals, representatives mentioned several technologies and devices in development to improve the current line of therapeutics. Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies. Specific highlights of this report include extensive research, company backgrounds, challenges, and validation techniques for therapeutic applications offered by the participating companies. These techniques include: • Radiation therapy • Implantable telescope technology • PharmacoSurgery • Mucosal penetrating products
Also available are complementary interviews with company representatives at the end of each section. The interviewees include: • President and CEO of Oraya Therapeutics • Marketing Director of VisionCare Ophthalmic Technologies • Chairman and CEO of Omeros • CMO of Kala Pharmaceuticals
Also included in this report is a demographic survey of researchers working in ocular disorders. Some of the concepts include ocular areas of research, promising therapeutic options, targets of interest, and challenges encountered.
CHAPTER 3:Oraya Therapeutics Radiotherapy platform • Automatic Positioning System (APS) • I-Guide • System software
Radiation dosing Potential complications and risk factors Competitive advantage Challenges and areas of improvement Future expectations Interview with Jim Taylor • Radiation therapy • Competitive advantage • Challenges encountered • Areas of improvement • Future expectations
CHAPTER 4:VisionCare Ophthalmic Technologies Company background Telescope technology Complications and challenges Interview with Reena Mishra • Company background • Telescope technology • Competitive advantage • Complications and challenges
CHAPTER 6:Kala Pharmaceuticals Company background Mucosal penetrating products (MPP) Competitive advantage Future endeavors Interview with Kim Brazzell • Company background • Mucosal penetrating products (MPP) • Challenges encountered • Competitive advantage • Future endeavor
CHAPTER 7:Platforms and Products
CHAPTER 8:Survey of Ocular Industry Areas of development Promising targets and therapies Challenges encountered
Table 2.1: Clinical status for common therapies for wet AMD Table 3.1 Platform specifications Table 4.1: Platform specifications Table 5.1: Targets and their clinical status Figure 6.1: Targets and their clinical status Table 7.1: Targets in clinical stages Table 7.2: Therapeutic platform specifications
Figure 8.1: Areas of research Figure 8.2: Ocular disorders of interest Figure 8.3: Promising therapies for ocular diseases Figure 8.4: Promising targets for ocular therapies Figure 8.5: Challenges encountered
People fighting cancer might have to wait longer to see a cancer specialist in the coming decades, as demand for treatment outpaces the number of oncologists entering the workforce, a new report released Tuesday...More >>
People fighting cancer might have to wait longer to see a cancer specialist in the coming decades, as demand for treatment outpaces the number of oncologists entering the workforce, a new report released Tuesday warns.More >>